Siegfried Holding AG · SIX:SFZN

Siegfried — FY2016 Earnings Presentation

18 slides from Siegfried's earnings presentation, Mar 14, 2017

  1. Slide 1: Welcome to the Media + Analysts' Conference

    Slide 1: Welcome to the Media + Analysts' Conference

    Welcome to the Media + Analysts’ Conference Zurich, March 14, 2017

  2. Slide 2: Important Notice

    Slide 2: Important Notice

    Important Notice This document is solely for use in connection with the presentation held by Siegfried Holding AG. It is furnished to you solely for your information and you may not reproduce it or redistribute to any other person. The contents of this document are to be kept strictly confidential b

  3. Slide 3: Agenda

    Slide 3: Agenda

    1. Highlights 2. Facts & Figures 3. Status and Strategy 4. Outlook Media + Analysts’ Meeting 2017 March 14, 2017 3

  4. Slide 4: Highlights

    Slide 4: Highlights

    Highlights — Sharp increase in sales to CHF 717.7 million, 49.3% increase in CHF (+47.3% in LC) — EBITDA CHF 104.2 million (+30.1%) before and 96.7 million after integration costs — Net profit of CHF 27.9 million below prior year due to integration costs, higher financing costs and tax expense vs. t

  5. Slide 5: Facts & Figures

    Slide 5: Facts & Figures

    1. Highlights 2. Facts & Figures 3. Status and Strategy 4. Outlook Media + Analysts’ Meeting 2017 March 14, 2017 5

  6. Slide 6: Net sales

    Slide 6: Net sales

    Net sales CHF million 2016 2015 Change CHF (LC) Drug Substances 557.9 333.2 +67.5% (+65.4%) Drug Products 159.8 147.4 +8.4% (+6.3%) Total 717.7 480.6 +49.3% (+47.3%) Comments — Organic sales growth with 6.7% above market — Drug Substance growth driven by acquisition effect of former BASF business. —

  7. Slide 7: Significant increase in operating profits

    Slide 7: Significant increase in operating profits

    Significant increase in operating profits In Mio. CHF 120.0 109.2 104.2 100.0 90.7 80.1 80.0 60.0 54.2 46.4 40.0 34.1 33.4 20.0 0.0 Gross profit EBITDA EBIT Net profit 2015 2016 — Non-recurring integration costs were CHF 7.5m on EBITDA and EBIT level (2015 CHF 3.0m) — This leads to the reported EBIT

  8. Slide 8: Dilution of operating margins due to acquisition

    Slide 8: Dilution of operating margins due to acquisition

    Dilution of operating margins due to acquisition In % 20.0% 18.9% 16.7% 15.2% 14.5% 15.0% 9.7% 10.0% 7.6% 7.1% 4.6% 5.0% 0.0% Gross profit margin EBITDA margin EBIT margin Net profit margin 2015 2016 — Dilutive effect from acquisition on operating margins (BASF API and supply business) — Negative im

  9. Slide 9: P&L

    Slide 9: P&L

    P&L CHF million 2016 2015 Net sales 717 729 480 571 Cost of goods sold – 608 509 – 389 919 Gross profit 109 220 90 652 Marketing and sales costs – 16 028 – 13 041 Research and development costs – 21 193 ** – 23 289 Admin and general overhead costs – 31 488 – 23 311 Other operating income 6 239 12 42

  10. Slide 10: Significant improvement of operating cash flow

    Slide 10: Significant improvement of operating cash flow

    Significant improvement of operating cash flow CHF million 2016 2015 Operating Cashflow before changes in NWC 95 907 65 025 Change in NWC –38 794 –41 950 Operating Cashflow 57 113 23 075 Purchase of PPE and intangibles (net) – 68 287 – 89 370 Acquisitions 2 157 – 160 361 Other investing activities 3

  11. Slide 11: Pay-out – proposal to the AGM on April 20, 2017

    Slide 11: Pay-out – proposal to the AGM on April 20, 2017

    Pay-out – proposal to the AGM on April 20, 2017 — The Board of Directors proposes a pay-out from the capital contribution reserves of CHF 2.00 per share (2016: CHF 1.80 per share) to the AGM on April 20, 2017 (in total appr. CHF 8.0m). — Pay-out from capital contribution reserve, tax free. — Remaini

  12. Slide 12: Status and Strategy

    Slide 12: Status and Strategy

    1. Highlights 2. Facts & Figures 3. Status and Strategy 4. Outlook Media + Analysts’ Meeting 2017 March 14, 2017 12

  13. Slide 13: Siegfried's new production network offers unique flexibility and integration

    Slide 13: Siegfried's new production network offers unique flexibility and integration

    Siegfried`s new production network offers an unique combination of flexibility and integration on a global base Media + Analysts’ Meeting 2017 March 14, 2017 13

  14. Slide 14: New offers at record level

    Slide 14: New offers at record level

    New offers at record level Sales potential new projects* Year acquired 2014 2015 2016 0 50 100 150 200 250 Mio CHF *For 5 years (2017-2021). = after risk adjustment Media + Analysts’ Meeting 2017 March 14, 2017 14

  15. Slide 15: EVOLVE strategy for 2016–2020

    Slide 15: EVOLVE strategy for 2016–2020

    Siegfried’s EVOLVE strategy for 2016–2020: Siegfried will further enhance its pure-play CDMO business model Fields of action  Strengthen offerings: – Expand global solida drug product footprint – Expand overall presence with own production facilities (e.g. US) – Enhance development setup Growth  G

  16. Slide 16: Outlook

    Slide 16: Outlook

    1. Highlights HY 2016 2. Facts & Figures 3. Status and Strategy 4. Outlook Media + Analysts’ Meeting 2017 March 14, 2017 16

  17. Slide 17: Outlook

    Slide 17: Outlook

    Outlook The Siegfried Group expects − high single-digit sales growth − Double-digit growth of EBITDA − improved EBITDA margin Media + Analysts’ Meeting 2017 March 14, 2017 17

  18. Slide 18: Thank you for your attention

    Slide 18: Thank you for your attention

    Siegfried expect more Thank you for your attention

Source: Internet Archive copy of siegfried.ch

More decks from Siegfried Holding AG

All 25 Siegfried decks